Scholarlink

Purpose <p>Combination treatments can shorten treatment time and reduce drug side effects. The aim of this study was to assess the efficacy of combined treatment using bedaquiline (BDQ) against clinical isolates of multidrug-resistant (MDR) <i>Mycobacterium tuberculosis</i> (<i>M. tuberculosis)</i>.</p> Methods <p>This cross-sectional study was performed on 15 drug-resistant isolates of <i>M. tuberculosis</i>. After determining the Minimum inhibitory concentration (MIC) of antibiotics, the fractional inhibitor concentration index (FICI) was evaluated using a checkerboard resazurin microtitration assay (REMA) to evaluate their interaction profiles against the <i>M. tuberculosis</i> isolates. The macrophage model was used to study the activity of synergistic compounds and the expression level of macrophage genes were evaluated by real-time PCR.</p> Results <p>All isolates had MIC ≥ 0.25&#xa0;µg/mL for BDQ. Of the 15 isolates, only 2 observed a synergistic effect between BDQ and other antibiotics. The expression of macrophage genes (<i>FABP5</i>,<i> HERG</i>,<i> RPL24</i>,<i> and SCARB1</i>) infected with these two isolates, was significantly increased by the combination of BDQ+ gemifloxacin (GEM), BDQ + Rifampicin (RIF), BDQ + moxifloxacin (MFX), and BDQ + isoniazid (INH) (<i>p</i> &lt; 0.01).</p> Conclusion <p>Despite resistance to BDQ, the combination treatments showed a positive effect in the macrophage cell line model. Therefore, it can be concluded that the combination treatment with BDQ may enhanced the innate immune response of macrophages against <i>M. tuberculosis</i> infection and also reduce the MIC of BDQ and other antibiotics in combination with it. This suggests a potential for more effective treatment for drug-resistant isolates.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Assessing the efficacy of combined treatment using bedaquiline against clinical isolates of multidrug-resistant Mycobacterium tuberculosis in vitro and the macrophage model

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月26日

查看全文
  • Kamal Ahmadi,
  • Nahid Madadi-Goli,
  • Mohsen Azizi,
  • Shima Hadifar,
  • Nayereh Ebrahimzadeh,
  • Morteza Masoumi,
  • Mahshid Nasehi,
  • Seyed Davar Siadat,
  • Abolfazl Fateh,
  • Farzam Vaziri

摘要

Purpose

Combination treatments can shorten treatment time and reduce drug side effects. The aim of this study was to assess the efficacy of combined treatment using bedaquiline (BDQ) against clinical isolates of multidrug-resistant (MDR) Mycobacterium tuberculosis (M. tuberculosis).

Methods

This cross-sectional study was performed on 15 drug-resistant isolates of M. tuberculosis. After determining the Minimum inhibitory concentration (MIC) of antibiotics, the fractional inhibitor concentration index (FICI) was evaluated using a checkerboard resazurin microtitration assay (REMA) to evaluate their interaction profiles against the M. tuberculosis isolates. The macrophage model was used to study the activity of synergistic compounds and the expression level of macrophage genes were evaluated by real-time PCR.

Results

All isolates had MIC ≥ 0.25 µg/mL for BDQ. Of the 15 isolates, only 2 observed a synergistic effect between BDQ and other antibiotics. The expression of macrophage genes (FABP5, HERG, RPL24, and SCARB1) infected with these two isolates, was significantly increased by the combination of BDQ+ gemifloxacin (GEM), BDQ + Rifampicin (RIF), BDQ + moxifloxacin (MFX), and BDQ + isoniazid (INH) (p < 0.01).

Conclusion

Despite resistance to BDQ, the combination treatments showed a positive effect in the macrophage cell line model. Therefore, it can be concluded that the combination treatment with BDQ may enhanced the innate immune response of macrophages against M. tuberculosis infection and also reduce the MIC of BDQ and other antibiotics in combination with it. This suggests a potential for more effective treatment for drug-resistant isolates.